IL308809A - T cell binding compounds and their uses - Google Patents

T cell binding compounds and their uses

Info

Publication number
IL308809A
IL308809A IL308809A IL30880923A IL308809A IL 308809 A IL308809 A IL 308809A IL 308809 A IL308809 A IL 308809A IL 30880923 A IL30880923 A IL 30880923A IL 308809 A IL308809 A IL 308809A
Authority
IL
Israel
Prior art keywords
cell engager
engager molecules
molecules
cell
engager
Prior art date
Application number
IL308809A
Other languages
English (en)
Hebrew (he)
Inventor
Johannes Brozy
Christoph Dahlhoff
Tobias Raum
Jochen S Pendzialek
Lisa Winkel
Markus Muenz
Nathan William Pierce
Agnieszka Kielczewska
Wentao Chen
Darren L Bates
Claudia Bluemel
Jonas Karl-Josef Honer
Original Assignee
Amgen Res Munich Gmbh
Amgen Inc
Johannes Brozy
Christoph Dahlhoff
Tobias Raum
Jochen S Pendzialek
Lisa Winkel
Markus Muenz
Nathan William Pierce
Agnieszka Kielczewska
Wentao Chen
Darren L Bates
Claudia Bluemel
Honer Jonas Karl Josef
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh, Amgen Inc, Johannes Brozy, Christoph Dahlhoff, Tobias Raum, Jochen S Pendzialek, Lisa Winkel, Markus Muenz, Nathan William Pierce, Agnieszka Kielczewska, Wentao Chen, Darren L Bates, Claudia Bluemel, Honer Jonas Karl Josef filed Critical Amgen Res Munich Gmbh
Publication of IL308809A publication Critical patent/IL308809A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
IL308809A 2021-06-04 2022-06-02 T cell binding compounds and their uses IL308809A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163197265P 2021-06-04 2021-06-04
US202163236547P 2021-08-24 2021-08-24
PCT/US2022/032006 WO2022256559A1 (en) 2021-06-04 2022-06-02 T cell engager molecules and uses thereof

Publications (1)

Publication Number Publication Date
IL308809A true IL308809A (en) 2024-01-01

Family

ID=82258382

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308809A IL308809A (en) 2021-06-04 2022-06-02 T cell binding compounds and their uses

Country Status (9)

Country Link
US (1) US20250129160A1 (enExample)
EP (1) EP4347654A1 (enExample)
JP (1) JP2024520666A (enExample)
KR (1) KR20240019218A (enExample)
AU (1) AU2022287014A1 (enExample)
CA (1) CA3221250A1 (enExample)
IL (1) IL308809A (enExample)
MX (1) MX2023014415A (enExample)
WO (1) WO2022256559A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022285741A1 (en) * 2021-06-04 2023-12-14 Amgen Inc. Anti-ccr8 antibodies and uses thereof
PE20240638A1 (es) 2021-07-14 2024-03-27 Genentech Inc Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso
PE20252286A1 (es) * 2023-01-18 2025-09-18 Genentech Inc Anticuerpos multiespecificos y usos de estos
WO2024248037A1 (ja) * 2023-05-30 2024-12-05 塩野義製薬株式会社 Ｃｃｒ８を抗原として認識する二重特異性抗体
CN122374018A (zh) * 2023-10-06 2026-07-10 美国安进公司 用于癌症治疗的组合疗法
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025259749A1 (en) * 2024-06-12 2025-12-18 Amgen Inc. Stable single-chain variable fragments
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2026019990A1 (en) * 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies
WO2026072755A2 (en) * 2024-09-26 2026-04-02 Amgen Inc. Single-chain fab proteins and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
EP3218413A4 (en) * 2014-11-12 2018-03-28 Memorial Sloan-Kettering Cancer Center Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
UA126657C2 (uk) * 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
AR107582A1 (es) * 2016-02-03 2018-05-16 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
JP7231158B2 (ja) * 2016-10-19 2023-03-01 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント Ｃｄ１３３結合剤およびその使用
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit

Also Published As

Publication number Publication date
JP2024520666A (ja) 2024-05-24
EP4347654A1 (en) 2024-04-10
KR20240019218A (ko) 2024-02-14
MX2023014415A (es) 2024-02-08
WO2022256559A1 (en) 2022-12-08
AU2022287014A9 (en) 2023-12-14
US20250129160A1 (en) 2025-04-24
CA3221250A1 (en) 2022-12-08
AU2022287014A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
GB2609554B (en) Anti-TCR antibody molecules and uses thereof
GB2595980B (en) Anti-TCR antibody molecules and uses thereof
ZA201906923B (en) Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3546561A4 (en) CO-CULTURE DEVICE AND CO-CULTURE PROCESS FOR A BACTERIA SUCH AS AN ANAEROBIC BACTERIA AND EPITHELIAL CELLS
SG11202107269XA (en) Modified cell expansion and uses thereof
GB2598218B (en) Anti-TCR antibody molecules and uses thereof
GB2607452B (en) Anti-TCR antibody molecules and uses thereof
PL3820906T3 (pl) Wielospecyficzne cząsteczki zastępcze wnt i ich zastosowania
DK2510084T3 (da) Stamcelleimmunmoduleringsanvendelsesfremgangsmåder og apparat
IL325457A (en) Cell culture systems and their use
IL304485A (en) Anti-cd123 binding compounds and their uses
IL284781A (en) LILRB3 binding molecules and uses thereof
SG11202104864QA (en) Multispecific binding constructs against checkpoint molecules and uses thereof
IL226761B (en) Reporter molecules are bound to cell membranes and used for cell separation
IL305794A (en) LILRB1 and LILRB2 binding molecules and their uses
GB2609770B (en) Cell lysis systems and methods
EP3652339A4 (en) BIOSENSORS FOR MEASURING CELL SIGNALING IN STRESSED AND HEALTHY CELLS
PL3592699T3 (pl) Układanie nanorurek węglowych w kanałach zamkniętych
ZA202210020B (en) Cd137 binding molecules and uses thereof
IL278832A (en) Improved molecules that bind 41GP
DK3588644T3 (da) Elektrokemisk reaktionsenhed og elektrokemisk reaktionscellestak
GB202019623D0 (en) Electrochemical methods and materials
GB201902732D0 (en) Pressure seal with built in testing system
HK1205747A1 (en) Modified adiponectin polypeptides and their uses
HK40109741A (en) T cell engager molecules and uses thereof